Comprehensive Support

From Preclinical to Commercialization

Curapath is your trusted CDMO partner for non-viral drug delivery programs, seamlessly supporting your journey from preclinical to commercial manufacturing. Our phase-appropriate approach ensures tailored process development and validation, alongside our extensive expertise in lipid and polymer novel excipients and nanoparticle formulations. Rely on Curapath’s precision and expertise to drive your drug delivery innovations forward. 

Transforming Patients Lives:

Complete Assistance Along Your Path to Market Authorization

Preclinical Development

We establish robust, scalable processes, implement analytical methods, and manufacture non-GMP pilot batches.

Clinical

Supply

We ensure seamless progress towards IND filing in novel functional excipient, drug substance and drug product. We support your project from candidate optimization to GLP tox studies towards GMP production.

Commercial Manufacturing

We provide comprehensive services for commercial scale manufacturing, GMP compliance and regulatory processes to bring products to market in an agile and reliable way.

Navigating the Complexities of Drug Development with Seasoned Expertise

Our expertise spans drug delivery systems, functional excipients and analytical methods. With a team of industry-leading subject matter experts, we provide our customers with the high-quality products they need to advance innovation in the cell and gene therapy space.

Our technical experts are specialists recognized worldwide in the in the following key areas:

Polymer & Lipid Excipients
Polymer and lipid excipients are essential components in pharmaceutical formulations, designed to enhance the stability, solubility, and bioavailability of drugs. These excipients play a pivotal role in ensuring the effectiveness and safety of a wide range of active pharmaceutical ingredients.
Non-Viral Gene Delivery
Non-viral drug delivery approaches are becoming increasingly important in pharmaceutical research and development due to their safety and versatility. These methods employ various nano carriers, such as lipid nanoparticles (LNP), polymer nanoparticles (PNP) and conjugates, to transport therapeutic agents into target cells.
Comprehensive
Analytical Methods
Adequate analytical methods to measure the product specific critical quality attributes (CQAs) are the foundation of quality control at Curapath. These methods are indispensable in confirming the identity, purity, and potency of drug products, ensuring regulatory compliance throughout the drug development and manufacturing process.

Products Tailored to You

Our dedication to staying at the forefront of our industry means that our catalog products, including proprietary and reference items, are constantly updated to reflect the latest advancements and trends. This guarantees that our customers have access to the most cutting-edge solutions in non-viral drug delivery systems.

Explore Our Resources

As a global organization, we are actively participating in events and projects that are at the core of our field. Explore our technical library composed of technical application notes, brochures, and case studies to better understand our core capabilities, services, and technology.

FEATURED RESOURCE

Product Catalog

FEATURED RESOURCE

Ionizable Lipids

Testimonials

At Curapath, customer satisfaction is our main target, and we deeply appreciate their valuable feedback. We are fully committed to delivering personalized support, high quality products and services. With a current Net Promoter Score (NPS) of 56, we proudly reflect a high level of customer satisfaction.

Quality Statement

Curapath (formerly PTS) quality system is based on Eudralex Vol 4, Part II for investigational Drug Substances and functional excipients, and on Eudralex Vol 4, Part I for investigational Drug Products.

Curapath owns a GMP certificate for the manufacture of investigational Drug Substances. Manufacturing authorization and GMP certificate for investigational Drug products is to be obtained by 2022.